A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
Conditions
Metastatic Castration-resistant Prostate Neoplasms · Metastatic Hormone-sensitive Prostate Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Florida Cancer Specialists, Sarasota, Florida, United States
Start Midwest, Grand Rapids, Michigan, United States
Washington University School Of Medicine, St Louis, Missouri, United States
Perlmutter Cancer Center at NYU Langone Brooklyn, Brooklyn, New York, United States
Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long Island, Mineola, New York, United States
NYU Langone Health, New York, New York, United States
Sidney Kimmel Cancer Center - Jefferson Health, Philadelphia, Pennsylvania, United States
Icon Cancer Centre Kurralta Park, Kurralta Park, Australia
Macquarie University, Macquarie University, Australia
Peter MacCallum Cancer Centre, Melbourne, Australia
Princess Alexandra Hospital, Woolloongabba, Australia
Hosp Univ Vall D Hebron, Barcelona, Spain
Hosp Univ Fund Jimenez Diaz, Madrid, Spain
Hosp. Univ. 12 de Octubre, Madrid, Spain
Hosp Univ Hm Sanchinarro, Madrid, Spain
Study leads
Janssen Research & Development, LLC Clinical Trial
Study Director
Janssen Research & Development, LLC